Introduction {#s1}
============

AMPARs mediate the majority of fast excitatory transmission in the central nervous system and play a key role in brain plasticity. AMPAR function is controlled by a multitude of auxiliary subunits ([@bib26]). These include TARPs ([@bib19]), cornichons ([@bib16]), Sol-1 ([@bib28]) and SynDIG1 ([@bib5]). Recently, we identified a novel AMPAR auxiliary subunit, CKAMP44, and characterized its modulation of AMPAR gating properties in CA1 and dentate gyrus neurons ([@bib8]; [@bib21]). Unlike other auxiliary subunits, CKAMP44 contains an N-terminal cystine-knot domain that in other proteins, e.g. growth factors ([@bib11]), was shown to stabilize the globular structure of the protein. The different auxiliary subunits exhibit distinct modulatory profiles. Since auxiliary subunits are differentially expressed in the brain, the specific combination in a particular cell type is likely to govern the AMPAR response to glutamate, as is the case for dentate gyrus granule cells, which express TARP γ-8 and CKAMP44. Both proteins increase the number of AMPARs on the cell surface, decrease the deactivation rate and increase glutamate affinity. However, they differ in the influence that they extend on AMPAR desensitization, recovery from desensitization, long-term and short-term potentiation ([@bib8]).

Here, based on homology with CKAMP44, we report on three novel CKAMP44-like proteins that were named CKAMP39, CKAMP52 and CKAMP59 and, together with CKAMP44, constitute the CKAMP family. Like CKAMP44, the newly identified CKAMPs are all single transmembrane domain proteins that possess an extracellular cystine-knot domain and an intracellular domain ending with a PDZ type II motif. Notably, novel CKAMP family members bind to GluA1 and GluA2 and modify AMPAR-mediated currents in heterologous expression systems.

Results {#s2}
=======

Identification of novel *CKAMP* genes in the mouse genome {#s2-1}
---------------------------------------------------------

To investigate whether CKAMP44 has homologues in rodents, we searched the genomic databases using either the complete sequence of the *CKAMP44* gene or the *CKAMP44* cystine-knot domain sequence as a reference. We found three genes with a high degree of similarity to CKAMP44 and named them according to the predicted molecular weight of their corresponding protein products---CKAMP39, CKAMP52 and CKAMP59 ([Figure 1A](#fig1){ref-type="fig"}). Due to the similarity in their peptide sequences (especially the cystine-knot motif), we classified these four proteins as the CKAMP family members.

![Identification and molecular characterization of CKAMP proteins.\
(**A**) Schematic drawing of CKAMP proteins, depicting the signal peptide (SP), cysteines (C) of the cystine knot, transmembrane domain (TM) and PDZ type II motif (EVTV). 'AI' indicates "AMPAR interacting" region, based on the GluA1 binding co-IP experiments from [@bib8]. (**B**) Protein sequence alignment of mouse CKAMP39, CKAMP44, CKAMP52 and CKAMP59. Amino acids marked in blue are similar or identical among CKAMP family members. Intensity of the blue color indicates the degree of similarity, with identical amino acid positions in the protein sequence highlighted by the most intense color. Green rectangles outline the predicted signal peptides, red rectangles---the predicted transmembrane domains, purple rectangles - putative AMPAR interacting regions and orange rectangle---the PDZ type II motif. Positions of cysteines belonging to the cystine-knot motif are indicated in black. Thick red lines in position 274 for CKAMP52 and 280 for CKAMP59 indicate insertion sites for additional aa sequences that are encoded by alternatively spliced exon 3 and exon 4, respectively. Thick green lines nearby C-termini indicate positions for flag-tag insertions. (**C**) Phylogenetic analysis of Shisa and CKAMP proteins, based on their protein sequence (average distance tree).](elife-09693-fig1){#fig1}

Like CKAMP44, all CKAMP proteins comprise a signal peptide, N-terminal cystine-knot extracellular domain, transmembrane domain and a large intracellular C-terminal domain, which terminates in a PDZ type II motif ([Figure 1A,B](#fig1){ref-type="fig"}). The predicted signal peptides vary in length, being 36, 30 and 22 amino acids for CKAMP39, CKAMP52 and CKAMP59, respectively ([Figure 1B](#fig1){ref-type="fig"}). Strikingly, cystine-knot domains exhibit a high degree of similarity and all eight cysteines are conserved among the family members ([Figure 1B](#fig1){ref-type="fig"}). Although cystine-knot containing proteins differ much in their function ([@bib3]; [@bib11]; [@bib27]), the purpose of cysteine-knots is similar, i.e. to form a tightly packed globular domain made of β-strands with several variable loops for stable protein-protein interaction. Thus, although sequences of the extracellular domains of CKAMP proteins have little homology beyond the cystine-knot core, it is likely that the extracellular region of all four proteins exhibit a similar β-strand structure. Each of the proteins possesses a predicted single short transmembrane domain (18--19 amino acids), and novel CKAMP family members have \~80% homology with the transmembrane domain of CKAMP44 ([Figure 1B](#fig1){ref-type="fig"}). Notably, a \~20 amino acid stretch immediately downstream of the transmembrane domain contains a conserved arginine-rich motif ([Figure 1B](#fig1){ref-type="fig"}). This is of particular interest, since this region of CKAMP44 was shown to be necessary for interaction with GluA1, and CKAMP44 mutants with a deletion of only 6 amino acids in this region did not bind to GluA1 when overexpressed in HEK293/T17 cells ([@bib8]). Finally, another conserved region in the protein sequence amongst CKAMP family members is the PDZ type II motif located at the very end of the C-terminal domain ([Figure 1B](#fig1){ref-type="fig"}). Thus, all CKAMP proteins end with the same EVTV stretch. Furthermore, another 5 amino acids upstream of the PDZ motif are also almost identical in CKAMP proteins. The PDZ motif is of functional importance as it mediates the interaction of CKAMP44 with PSD95, which allows anchoring of AMPARs within synapses of dentate gyrus granule cells ([@bib8]).

At the time of CKAMP family identification, the genes of the CKAMP family members had not yet been recorded in the Refseq database. Currently, based on their similarity to *Shisa* genes, the *Ckamp* genes are termed in the genome database as *Shisa6* (CKAMP52), *Shisa7* (CKAMP59), *Shisa8* (CKAMP39) and *Shisa9* (CKAMP44). Shisa 1--3 proteins were studied in embryonic development of *Xenopus laevis*, where they were found to inhibit Wnt and FGF signaling by retention of their receptors in ER ([@bib12]; [@bib25]). However, CKAMP family members differ significantly from Shisa2-5 proteins ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, Shisa1 protein does not have a mouse homolog) and form a separate cluster on the phylogenetic tree ([Figure 1C](#fig1){ref-type="fig"}, see also [@bib13]). There are \~70 amino acids that are largely conserved in the CKAMP cluster, but not in the Shisa cluster ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Furthermore, Shisa proteins are much shorter than CKAMPs, being 197-295 and 399-541 amino acids, respectively. Interestingly, the GluA1-interacting region of CKAMP44 exhibits a high degree of similarity to other CKAMPs, but not to that of Shisa proteins ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Finally, Shisa proteins do not contain a PDZ binding motif at their C-terminus. Based on these considerations, we propose that CKAMP members constitute a protein family distinct from the Shisa protein family ([Figure 1C](#fig1){ref-type="fig"}).

Novel CKAMP proteins are expressed in the mouse brain and interact with AMPARs in HEK293/T17 cells {#s2-2}
--------------------------------------------------------------------------------------------------

We amplified open reading frames (ORFs) for the three novel CKAMP proteins using mouse brain-derived mRNA and confirmed the sequence of the corresponding proteins. Since at least 30 clones per CKAMP family member were analyzed, we were able to estimate the relative expression levels of different CKAMP splice isoforms in the brain. While CKAMP39 had only one splice variant, both CKAMP52 and CKAMP59 had two splice isoforms ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) that differed in protein coding sequences. In the subsequent experiments, we utilized the most abundant versions of CKAMPs, i.e. CKAMP52 and CKAMP59 lacking exon 3 and exon 4, respectively (note that alignments in [Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} are performed for exon 3- and exon 4-lacking versions). Exon 3 of CKAMP52 and exon 4 of CKAMP59 encode 32 and 17 intracellular amino acids, respectively, downstream of the AMPAR-interacting domain and upstream of the PDZ motif. Interestingly, there are also two splice variants of CKAMP44 ([@bib21]), but alternatively spliced mRNA was not reported for mouse Shisa family members.

Previously, we demonstrated that CKAMP44 is expressed exclusively in the brain ([@bib21]). Based on gene expression database BioGPS, we found that the new members of the CKAMP family are also expressed exclusively in the brain ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). In situ hybridization of adult mouse brain sections with oligo probes against CKAMP39, CKAMP52 and CKAMP59 mRNAs revealed that each of the novel CKAMP family proteins exhibited a region-specific expression pattern within the brain ([Figure 2A](#fig2){ref-type="fig"}). CKAMP39 expression was restricted to two brain regions, namely the cerebellum and olfactory bulb, which were also the only brain regions with significant CKAMP39 expression according to the BioGPS database ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Both CKAMP52 and CKAMP59 were expressed in the hippocampus, but CKAMP59 was also expressed in the cortex and olfactory bulb, whereas CKAMP52 was expressed in the cerebellum and septum. CKAMP39 is absent and CKAMP52 is barely detectable in the brain of embryonic day 17 (E17) mice. In contrast, there is a strong signal for CKAMP59 already prenatally. Postnatally, there is little change in the expression pattern of any of these CKAMPs, except for an upregulation of CKAMP39 and CKAMP52 in the cerebellum and olfactory bulb and a modest downregulation of CKAMP59 in the thalamus and brainstem ([Figure 2A](#fig2){ref-type="fig"}).

![Expression pattern of CKAMPs and their interaction with AMPARs.\
(**A**) Transcription of *CKAMP* genes as visualized by in situ hybridization of brain sections obtained from mice at different developmental ages. Abbreviations: CB - cerebellum, CX - cortex, HIP - hippocampus, OB - olfactory bulb, SEP - septum. (**B**) and (**C**) All members of the CKAMP family interact with GluA1 and GluA2, respectively. HEK293/T17 cells were transfected with GluA1 (**B**) or GluA2 (**C**) together with one of the indicated flag-tagged CKAMPs or with EGFP as a control. Proteins were immunoprecipitated using anti-flag antibody. All flag-tagged CKAMPs, but not EGFP, co-precipitated GluA1 (**B**) or GluA2 (**C**) from the total protein fraction. Input corresponds to \~9% of GluA1 or \~3% of GluA2 co-immunoprecipitation experiment.](elife-09693-fig2){#fig2}

To determine whether CKAMP39, CKAMP52 and CKAMP59 interact with AMPARs, we inserted a flag-tag at the non-conserved C-terminal part of the proteins, and co-expressed flag-tagged CKAMPs along with GluA1 or GluA2 in HEK293/T17 cells. With an anti-flag antibody, GluA1 and GluA2 co-immunoprecipitated from protein samples of HEK293/T17 cells co-expressing flag-tagged CKAMP39, CKAMP52 or CKAMP59 ([Figure 2B](#fig2){ref-type="fig"}), showing that all novel CKAMPs bind to GluA1 and GluA2 in a heterologous expression system. All CKAMPs had two bands on Western blot, indicating their likely glycosylation that was shown previously for CKAMP44 ([@bib21]).

Novel CKAMP members modify AMPAR-mediated currents in heterologous expression systems {#s2-3}
-------------------------------------------------------------------------------------

To characterize the functional consequences of the interaction between the CKAMP family members and AMPARs, we performed electrophysiological experiments employing *Xenopus Laevis* oocytes. To investigate how gating properties are modulated by the novel CKAMPs, we performed fast perfusion patch-clamp recordings on outside-out macropatches pulled from oocytes expressing either GluA1 or GluA2(Q) alone, or with CKAMP39 or CKAMP52. An analysis of the effect of CKAMP59 on AMPAR gating in oocytes was not possible, as this auxiliary subunit was not sufficiently expressed in this heterologous expression system as revealed by the absence of detectable protein in Western-blot analysis ([Figure 3A](#fig3){ref-type="fig"}). Consistently, no significant change in AMPAR gating was observed for the co-expression of GluA1 or GluA2(Q) with CKAMP59. In contrast, CKAMP39 and CKAMP52 exhibited protein levels comparable to CKAMP44 ([Figure 3A](#fig3){ref-type="fig"}), and influenced AMPAR gating properties differentially. Neither CKAMP39 nor CKAMP52 modulated the GluA1-mediated deactivation time constant (τ~deact~), but both increased τ~deact~ of GluA2(Q)-mediated currents ([Figure 3B](#fig3){ref-type="fig"} and [Supplementary file 1A---table 1](#supp1){ref-type="supplementary-material"}). Both proteins also had no influence on the GluA1-mediated desensitization time constant (τ~des~), but significantly reduced τ~des~ of GluA2(Q)-mediated currents ([Figure 3C](#fig3){ref-type="fig"}). There was a trend towards increased steady-state current amplitude (as a percentage of maximal current) during the 500 ms glutamate application in the oocyte patches for GluA1 with CKAMP52 (see below for the significant effect on steady-state currents in HEK293/T17 cells), and a significant reduction in steady-state current amplitude of GluA2(Q)-mediated currents by CKAMP39 ([Figure 3C](#fig3){ref-type="fig"} and [Supplementary file 1A---table 1](#supp1){ref-type="supplementary-material"}). The time constant of recovery from desensitization (τ~recovery~) of GluA1- and GluA2(Q)-mediated currents was increased by CKAMP39, whereas there was only a small increase and decrease of τ~recovery~ of GluA1- and GluA2(Q)-mediated currents, respectively, when co-expressing CKAMP52 ([Figure 3D](#fig3){ref-type="fig"} and [Supplementary file 1A---table 1](#supp1){ref-type="supplementary-material"}).

![Modulation of AMPAR-mediated currents in Xenopus laevis oocytes.\
(**A**) Western blot analysis on flag-tagged CKAMPs in Xenopus laevis oocytes. CKAMP39, CKAMP44, CKAMP52 & CKAMP59 where injected at 1, 3, 5 & 10 ng/oocyte, respectively (UI-un-injected oocytes). (**B**) Deactivation rate (*τ*~deact~), (**C**) desensitization rate (*τ*~des~) and steady-state amplitude and (**D**) weighted time constant of recovery from desensitization (*τ*~recovery~) of GluA1- and GluA2(Q)-mediated currents. Deactivation and desensitization were tested by application of 10 mM glutamate for 1 ms and 500 ms, respectively, onto macropatches of oocytes. *τ*~recovery~ was estimated with application of two 100 ms glutamate pulses with different inter-pulse intervals. Example currents are shown on the left of the quantification (mean ± SEM).](elife-09693-fig3){#fig3}

We previously showed that CKAMP44 increases glutamate potency ([@bib21]). A comparable decrease in glutamate EC50 was observed when GluA1 or GluA2 was expressed with CKAMP39 or CKAMP52. The most dramatic change was seen when expressing GluA2 together with CKAMP52; the EC50 was more than 10 fold smaller for CKAMP52-bound GluA2 compared to GluA2 alone ([Figure 4A](#fig4){ref-type="fig"}). CKAMP39 and CKAMP44, but not CKAMP52, influenced not only the potency of glutamate, but also that of the AMPAR desensitization blocker cyclothiazide (CTZ). Thus, there was an increase in the CTZ EC50 when co-expressing GluA1 with CKAMP39, and GluA2 with CKAMP39 or CKAMP44 ([Figure 4B](#fig4){ref-type="fig"} and [Supplementary file 1B---table 2](#supp1){ref-type="supplementary-material"}).

![Influence of CKAMP proteins on glutamate and CTZ potency.\
(**A**) Glutamate potency for GluA1 or GluA2(Q) expressed along with CKAMP39, CKAMP44 or CKAMP52 in Xenopus laevis oocytes. Responses to increasing concentration of glutamate were recorded in the presence of 0.1 mM CTZ applied 10 s before and during glutamate application to reach equilibrium steady-state currents. Responses were normalized to the response obtained for 1mM glutamate. (**B**) CTZ potency for GluA1 or GluA2(Q) expressed along with CKAMP39, CKAMP44 or CKAMP52 in Xenopus laevis oocytes. Responses to 1 mM glutamate were recorded in the presence of increasing concentrations of CTZ after a 10 s incubation of the oocyte with the respective CTZ concentration without glutamate. Current responses were normalized to the response obtained with 0.1 mM CTZ after subtraction of the current induced by 1 mM glutamate without CTZ. The respective EC50 values (mean ± SEM) were calculated from fits to data obtained from individual oocytes.](elife-09693-fig4){#fig4}

CKAMP59 is well expressed in HEK293/T17 cells as revealed by Western blot analysis ([Figure 2B](#fig2){ref-type="fig"}) in contrast to the oocytes. Hence, to investigate the influence of CKAMP59 on AMPAR-mediated currents, we expressed this auxiliary subunit along with GluA1 or GluA2(Q) in HEK293/T17 cells. To be able to compare the influence of CKAMP59 with that of the other auxiliary subunits, we also investigated AMPAR-mediated currents in HEK293/T17 cells that co-expressed CKAMP39 or CKAMP52. In contrast to the other auxiliary subunits, CKAMP59 did not modulate GluA1- or GluA2(Q)-mediated current kinetics. However, there was a significant reduction in GluA2(Q)-mediated current amplitude. Co-expression of CKAMP39 and CKAMP52 also reduced AMPAR-mediated current amplitude (GluA1-current amplitude was reduced only by CKAMP39) ([Figure 5A](#fig5){ref-type="fig"} and [Supplementary file 1C---table 3](#supp1){ref-type="supplementary-material"}). A cell surface biotinylation assay performed in HEK293/T17 cells co-transfected with AMPARs and CKAMPs showed that all CKAMP family members, except for CKAMP52, lead to a reduction in surface expression of GluA1 and GluA2 protein. These results can be accounted for by a reduction of total expression of GluA1 and GluA2, and by reduced GluA2 forward trafficking or stabilization of GluA2 on the cell surface as indicated by the reduced ratio of surface to total protein. Interestingly, CKAMP52 increased the ratio of surface to total GluA1 expression, suggesting that this auxiliary protein exerts an opposite influence on forward trafficking or stabilization of GluA1 and GluA2 ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Supplementary file 1D---table 4](#supp1){ref-type="supplementary-material"}).

![Modulation of AMPAR-mediated currents in HEK293/T17 cells.\
(**A**) Peak current amplitude, (**B**) deactivation rate (τ~deact~), (**C**) desensitization rate (τ~des~) and steady-state amplitude and (**D**) τ~recovery~ of GluA1- and GluA2(Q)-mediated currents. Deactivation and desensitization were tested by application of 1 mM glutamate for 1 ms and 100 ms, respectively. τ~recovery~ was analyzed with application of two 1 ms glutamate pulses with different inter-pulse intervals. Example currents are shown on the left of the quantification (median ± IQR).](elife-09693-fig5){#fig5}

The strong reduction of surface AMPAR expression precluded an analysis of current kinetics by fast-application of glutamate onto outside-out patches. Thus, we performed an analysis using fast-application of glutamate onto whole HEK293/T17 cells instead. The expected solution exchange time is considerably slower when using whole cells instead of outside-out patches ([@bib1]). Nevertheless, the analysis allowed us to draw conclusions about the influence of CKAMP family members on AMPAR kinetic properties. Thus, CKAMP39 and CKAMP52 modulated AMPAR gating in HEK293/T17 cells similarly to what we observed in oocytes with an increase in GluA2(Q) τ~deact~ by CKAMP52 ([Figure 5B](#fig5){ref-type="fig"} and [Supplementary file 1C---table 3](#supp1){ref-type="supplementary-material"}), a decrease in GluA2(Q) τ~des~ by CKAMP39, an increase in GluA1 steady-state current amplitude by CKAMP52, and a reduction of the GluA2(Q) steady-state current amplitude by CKAMP39 ([Figure 5C](#fig5){ref-type="fig"} and [Supplementary file 1C---table 3](#supp1){ref-type="supplementary-material"}). Recovery from desensitization was analyzed in HEK293/T17 cells with a protocol that differed from that used in oocyte experiments, where we applied two 100 ms glutamate pulses with different interpulse intervals. In HEK293/T17 cell experiments, we applied two 1ms glutamate pulses. The rational was to probe whether CKAMP39 influences AMPAR recovery from desensitization also when glutamate is applied only for very short time periods, thus mimicking the short presence of glutamate in the synaptic cleft. Indeed, CKAMP39 slowed the recovery from desensitization of GluA1- and GluA2(Q)-mediated currents also when tested with this modified protocol ([Figure 5D](#fig5){ref-type="fig"} and [Supplementary file 1C---table 3](#supp1){ref-type="supplementary-material"}). The effect was comparable to that of CKAMP44, which modulates synaptic short-term plasticity in dentate gyrus granule cell synapses by slowing recovery from desensitization ([@bib8]).

There were some differences in the modulation of GluA2(Q)-mediated currents in HEK293/T17 cells and oocytes. Thus, CKAMP39 increases τ~deact~ in oocytes, but not in HEK293/T17 cells. In addition, τ~des~ was reduced by co-expression with CKAMP52 in oocytes, but not in HEK293/T17 cells. Finally, the steady-state current amplitude was increased by CKAMP52 in HEK293/T17 cells, but not in oocytes. In conclusion, the new CKAMP family members display very distinct modulatory effects on AMPAR gating. Like the prototypical TARP auxiliary subunits ([@bib6]), the CKAMP family affects AMPAR in a subunit-specific manner.

Discussion {#s3}
==========

In recent years, several labs have employed large proteomic screens to search for AMPAR interacting proteins, which resulted in the identification of new AMPAR auxiliary (or auxiliary-like) subunits, such as CKAMP44 ([@bib21]), cornichons ([@bib16]) and GSG1L ([@bib17]; [@bib18]). In this study, we searched a genomic and transcriptomic databases, and identified three new proteins that, together with CKAMP44, form the CKAMP family of AMPAR auxiliary-like proteins. Presumably, evolutionarily the CKAMPs and Shisa proteins descend from the same protein family. The Shisa proteins were shown to be involved in fibroblast growth factor receptor maturation and degradation during embryogenesis in *Xenopus laevis* oocytes ([@bib12]; [@bib25]). All CKAMPs exhibited a significant homology in the region of CKAMP44 that is necessary for AMPAR binding ([@bib8]). Thus, it is likely that, similar to CKAMP44, a stretch of amino acids immediately downstream of the transmembrane regions of novel CKAMP proteins is involved in interaction with AMPARs. All CKAMPs possess an extracellular cystine-knot motif that was shown to be important for modulation of AMPAR gating, and an identical intracellular PDZ-domain binding motif ([@bib8]). All CKAMPs bind to GluA1 and GluA2 and modify GluA1 and/or GluA2 currents in two heterologous systems, making them likely candidates for AMPAR auxiliary subunits in vivo. Importantly, despite their structural similarities, the members of the CKAMP family differ enormously in their modulation of AMPAR-mediated currents. Only the function of CKAMP39 resembles that of CKAMP44 ([@bib8]), and indeed this subunit also displays the highest homology with CKAMP44. CKAMP39 had a pronounced effect on the recovery from desensitization, similar to CKAMP44, suggesting that it might also modulate synaptic short-term plasticity as was observed for CKAMP44 in dentate gyrus granule cells ([@bib8]). The reduction of surface AMPAR number by all three CKAMPs in HEK293/T17 cells was unexpected, since CKAMP44 has the opposite effect on AMPARs of granule cells, possibly by promoting trafficking of AMPARs to the cell surface. The reduction in surface AMPAR number by the novel CKAMP family members was mainly due to a reduction in total AMPAR number in the cell. However, changes in the ratio of surface/total AMPAR number indicate that the novel CKAMP family members also influence the forward trafficking or stability of AMPARs on the cell surface.

The fact that some parameters of GluA2(Q)-mediated currents were modulated only in HEK293/T17 cells, others only in oocytes, cannot be explained by differences in AMPAR-composition, since the same GluA2(Q)-flip version of this subunit was expressed in both expression systems. However, one explanation could be the different recording conditions used for HEK293/T17 cells and oocytes. Thus, there were differences in room temperature (17^o^C versus 22^o^C), patch size (macropatches of oocytes versus lifted whole HEK293/T17 cells) and the holding potential (-70 versus -120 mV).

Overall, the novel CKAMP family members greatly expand the pool of AMPAR auxiliary-like proteins expressed in the brain. CKAMP52 was also identified as an AMPAR interacting protein in recent proteomic screens ([@bib17]; [@bib18]), showing that at least this CKAMP family member interacts with AMPARs in the brain. It is not clear why CKAMP39 and CKAMP59 were not identified as AMPAR interacting proteins, but it is possible that their expression level is too low or that their interaction is too loose for identification in the proteomic screens. The highly diverse expression pattern of CKAMP family members together with their unique biophysical profile make them strong candidates for region-specific AMPAR modulation. Future studies should unravel how different CKAMPs influence synaptic function by modulating expression and gating kinetics of AMPARs. Yet another effect of CKAMP family members might be an influence on neuron morphology as described for CKAMP44 and TARP γ-8, which increase spine number by augmenting surface AMPAR expression ([@bib8]).

Materials and methods {#s4}
=====================

Bioinformatics analysis {#s4-1}
-----------------------

Signal peptides were analyzed using SignalP 4.1 software ([@bib14]) (<http://www.cbs.dtu.dk/services/SignalP/>). Transmembrane domains were identified using TMHMM 2.0 software ([@bib9]) (<http://www.cbs.dtu.dk/services/TMHMM/>) and PredictProtein ([@bib24]) ([www.predictprotein.org](http://www.predictprotein.org)). Alignment of protein sequences and phylogenetic analysis was performed using Jalview ([@bib20]; [@bib23]) ([www.jalview.org](http://www.jalview.org)). The alignments of CKAMP proteins and of CKAMP and Shisa proteins were done using ProbCons ([@bib2]) and Clustal ([@bib10]) tools, respectively. The phylogenetic tree of Shisa proteins and CKAMPs was obtained utilizing average distance methods. Expression of CKAMP family members in different tissues was retrieved from gene expression BioGPS database (<http://biogps.org/>), GNF1M dataset for CKAMP39 and MOE430 dataset for CKAMP52 and CKAMP59.

Molecular cloning {#s4-2}
-----------------

RNA was isolated from the whole mouse brain and cDNA was synthesized as described before ([@bib7]). We used the following primers to amplify CKAMP39, CKAMP52 and CKAMP59:

C39F = 5'TAGGATCCGCCACCATGGAGCGCGCTGGGGCGCGGGGACAG

C39R = 5'GCACTAGTCTAGACCGTGACCTCGGCTTTGC

C52F = 5'ATGGATCCGCCACCATGGCGCTGCGCCGCCTCCTG

C52R = 5'CGACTAGTTCACACGGTCACTTCAGTCTTGCTGGC

C59F = 5'TAGGATCCGCCACCATGCCGGCCCTGCTGCTGCTC

C59R = 5'GCCACTAGTTCAGACAGTCACTTCGTTCTTGCTG

CKAMPs were amplified from cDNA using LA Taq polymerase with GC-rich buffer (Clontech-Takara Bio, France) for 5 cycles. PCR products were purified and re-amplified using PfuUltraII (Agilent, USA) for 30 more cycles. The resulting PCR products were digested by BamHI and SpeI and ligated into the pRK5 vector or an AAV vector with the human synapsin promoter, IRES and EGFP (pAAV-Syn-IRES-EGFP) ([@bib21]). CKAMP ORFs were sequenced and only those that corresponded to sequences from the genomic database were used in the subsequent experiments. To estimate the abundance of different splice-variants in the brain, at least 30 clones per each CKAMP family member were analyzed.

To generate flag-tagged versions of CKAMPs, we inserted a flag-tag sequence close to the non-conserved terminal region of CKAMPs (upstream to PDZ type II motif). The insertions were made using site-directed mutagenesis via two consecutive rounds of extension PCR, re-ligating flag-tagged PCR fragments using BspEI/SalI for CKAMP39 and XhoI/SalI for CKAMP52 and CKAMP59. The primers that we utilized for flag-tag insertion are shown below:

C39ctf-for = 5'CATCCGGAGGACTTGCCTGCGTTGC

C39ctf-rev1 =

5'CTTGTCATCGTCATCCTTGTAATCGATATCATGATCTTTATAATCACCG

CTCAGGTGCCGGGGTCCTC

C39ctf-rev2 = 5'TCTGTCGACTCTAGTCTAGACCGTGACCTCGGCTTTGCTGTTGGTGT

GCTTGTCATCGTCATCCTTGTAATCG

C52ctf-for = 5'GCCTCGAGCGCGCCTGGTGTCTCAG

C52ctf-rev1 = 5'CTTGTCATCGTCATCCTTGTAATCGATATCATGATCTTTATAATCAC

CAGTGCGCAGGTGCTGGGGCAG

C52ctf-rev2 = 5'TCTGTCGACTCTAGTTCAGACAGTCACTTCGTTCTTGCTGGCGTG

CTTGTCATCGTCATCCTTGTAATCG

C59ctf-for = 5'CACTTCCTCGAGAACGGCCACGCAG

C59ctf-rev1 = 5'CTTGTCATCGTCATCCTTGTAATCGATATCATGATCTTTATAATCA

CCTGTGTAGCAGGTGTGATGGC

C59ctf-rev2 = 5'TCTGTCGACTCTAGTTCACACGGTCACTTCAGTCTTGCTGGCGTG

CTTGTCATCGTCATCCTTGTAATCG

Western blot analysis and immunoprecipitation of proteins that were expressed in HEK293/T17 cells {#s4-3}
-------------------------------------------------------------------------------------------------

For immunoprecipitation experiments, an STR-tested and authenticated HEK293/T17 cell line was used (American Type Culture Collection, CRL-11268, ATCC, USA). All cell cultures were tested for mycoplasma contamination prior to experiments using PCR Mycoplasma Test Kit I/C (PK-CA91-1024, PromoCell GmbH, Germany). Cell lines utilized in the study are not mentioned in the list of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee. Both Western-blot and immunoprecipitation were performed as previously described ([@bib8]). Briefly, HEK293/T17 cells were co-transfected with CKAMP44, CKAMP39, CKAMP52, CKAMP59 (in pRK5) or EGFP expression (pEGFP-C1) plasmids together with a GluA1 or GluA2 expression plasmid (in pRK5). Two days post-transfection, protein was collected and affinity-purified with an agarose-bound flag antibody (Anti-FLAG M2 Affinity Gel, Sigma-Aldrich, Germany) as previously described ([@bib8]). For immunoprecipitation we used 350 μg of total protein. Immunoprecipitated proteins were eluted by 50 μl of 3Xflag peptide solution (Sigma-Aldrich, Germany). Denatured whole protein (6-10 μg) and immunoprecipitated (10-25 μl) samples were separated by SDS-PAGE and transferred onto PVDF membranes that were probed with the mouse anti-flag M2 antibody (1:2000, F1804, Sigma-Aldrich, Germany) and rabbit GluA1 (1:1000, Santa Cruz, Germany) or mouse GluA2 antibody (MAB397, 1:500, Millipore, Billerica, MA, USA)

Cell surface biotinylation assay {#s4-4}
--------------------------------

For cell surface biotinylation assay, HEK293/T17 cells were co-transfected with pRK5-CKAMP39, -CKAMP52, -CKAMP59 or pAcGFP1-Mem (Clontech-Takara Bio, France) plasmids together with pRK5-GluA1-flip or pRK5-GluA2(Q)-flip plasmids using Lipofectamine 2000 reagent (Invitrogen, Germany). Forty-eight hours after transfection, cells were washed once with ice-cold PBS (pH 8.0). Cells were biotinylated at room temperature for 30 min with 0.8 mM solution of EZ-Link Sulfo-NHS-SS-Biotin reagent (Pierce, Rockford, IL) prepared in PBS (pH 8.0). Cells were subsequently washed with 50 mM Tris (pH 8.0) to quench any non-reacted biotinylation reagent, and twice with ice-cold PBS (pH 8.0) to remove excess biotinylation reagent. To capture biotinylated surface proteins, total protein was collected and affinity-purified with EZview Red Streptavidin Affinity Gel (Sigma-Aldrich, Germany) using manufacturer\'s protocol. Denatured total (5 μl) and biotinylated surface protein (10 μl) samples were separated by SDS-PAGE, and transferred onto PVDF membranes that were probed with mouse anti-GluA1 antibody (1:1500) or mouse anti-GluA2 antibody (1: 500) (MAB2263 and MAB397, respectively, both from Millipore, Billerica, MA, USA). For loading control, mouse anti-beta Actin antibody (1:4000, MA5-15739, Thermo Fisher Scientific, Rockford, USA) was used. Surface protein was normalized for equal protein concentration. Relative quantification of surface GluA1 or GluA2 expression was carried out by densitometry of western blots using ImageJ software (<http://imagej.nih.gov/ij>).

HEK cell transfection and electrophysiology {#s4-5}
-------------------------------------------

HEK293/T17 cell lines stably expressing GluA1-flip or GluA2(Q)-flip were grown and maintained using standard protocols. For electrophysiological recordings, cells were transfected using Lipofectamine 2000 (Invitrogen, Germany) and pRK5-CKAMP39, -CKAMP52 or -CKAMP59 together with pEGFP-C1 (Clontech-Takara Bio, France) or pEGFP-C1 alone. Cells were recorded 24--72 h post-transfection. Fast application of glutamate onto lifted HEK293/T17 cells was performed as described ([@bib4]) using theta glass tubing mounted onto a piezo translator. AMPAR-mediated currents were evoked by a 1 ms glutamate pulse for analyzing amplitude and deactivation, by a 100 ms glutamate pulse for analyzing desensitization and steady-state current amplitude, and by two 1ms pulses with 10, 30, 100, 300, 1000 and 3000 inter-event interval for analyzing recovery from desensitization. Application pipettes were tested by perfusing solutions with different salt concentrations through the two barrels onto open patch pipettes and recording current changes with 1 and 100 ms transitions of the application pipette. Only application pipettes with 20--80% rise times below 100 µs and with a reasonable symmetrical on- and offset were used. However, the expected solution exchange time is considerably slower with the use of whole cells instead of outside-out patches ([@bib1]). The application solution contained (in mM): 135 NaCl, 10 HEPES, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 5 glucose (pH 7.2). Whole-HEK293/T17 cell recordings were performed at room-temperature using pipettes pulled from borosilicate glass capillaries with a resistance of 3-- 5 MΩ when filled with the following solution (in mM): 120 Cs-gluconate, 10 CsCl, 8 NaCl, 10 HEPES, 10 phosphocreatine-Na, 0.3 GTP, 2 MgATP, 0.2 EGTA (pH 7.3, adjusted with NaOH). Liquid junction potentials were not corrected. AMPAR-current deactivation and desensitization were fitted with two exponentials, and the weighted tau (𝜏~w~) was calculated as 𝜏~w~ = (𝜏~f~x× a~f~) + (𝜏~s~x× a~s~), where a~f~ and a~s~ are the relative amplitudes of the fast (𝜏~f~) and slow (𝜏~s~) exponential components.

In situ hybridization {#s4-6}
---------------------

The in situ hybridization was done as described before ([@bib22]). Briefly, horizontal brain sections from adult C57Bl/6 mice were cut on the cryostat (Leica Microsystems, Germany) and hybridized with one of the following radiolabeled oligodeoxyribonucleotide probes:

Ckamp39ins1 = 5'TGAGAAGTTCTGTCAGTGTCCTGGTCACCGTGCGCCGAGC

Ckamp52ins1 = 5'AATGTCAGCCAGAGCCCTGTGGATGTTCATCTCTCGCGGA

Ckamp59ins1 = 5'GCGGCATAGCACGCCAGTCGAGGTTGGAGGGCTTCATGGTGTT

The oligodeoxyribonucleotide probes were 3′ end-labeled by terminal deoxynucleotidetransferase and (a)-^33^P-dATP (Hartmann Analytic, Germany). Brain sections were then hybridized over night in, 4 x× SSC (Saline-sodium citrate buffer, 0.6 M NaCl, 0.06 M sodium citrate), 50% formamide, 10% dextrane and 1 pg/μl labeled oligodeoxyribonucleotide probes at 42◦° C and subsequently washed at 55◦°C for 30 min, dehydrated and exposed to Kodak R X-omat AR film for 1 week.

Oocyte preparation, electrophysiology and Western blot analysis {#s4-7}
---------------------------------------------------------------

Stage V--VI *Xenopus laevis* oocytes were prepared, injected with cRNA as previously described ([@bib15]). Whole-cell two electrode voltage clamp (TEVC) recordings were used for estimation of current amplitude before proceeding to patch-clamp recordings and for determination of EC50 values for glutamate and CTZ. TEVC recordings were performed at 17^o^C, at holding potential of −70mV, using GeneClamp500 connected to digidata1322A and pCLAMP8.2 (Axon Instruments). Data was analyzed by pCLAMP8.2 and ORIGIN 8 (Origin Lab Corp.) for estimation of the respective EC50s. For outside-out macropatch recordings the vitelline membrane was removed using forceps. Recordings were performed at 17^o^C, at membrane potential of -−120mV, using Axopatch 200B amplifier connected to digidata1322A and pCLAMP8.2 (Axon Instruments, Foster City, CA). For rapid solution exchanges, a double-barrel glass (theta tube) mounted on a piezoelectric translator (Burleigh, Fishers, NY) was used as previously described ([@bib15]). Patch electrodes were fabricated from borosilicateglass with a low resistance of 0.3--1 MΩ. Receptor deactivation and desensitization were measured by applying glutamate (10 mM) for 1 ms and 500 ms, respectively. Recovery from desensitization was estimated with the two-pulse protocol in which a constant 100 ms application of glutamate (10 mM) was followed by a 100 ms test pulse applied at different time intervals. Western-blot analysis was done as previously described ([@bib15]) on protein homogenates from 10 oocytes for each sample. Blots were probed with anti-Flag antibody (1:2000; monoclonal anti-FLAG M2, Sigma-Aldrich, Israel) and visualized using ChemiDoc XRS system (Bio-Rad Laboratories). GluA1-flip and GluA2(Q)-flip were injected at 1ng cRNA/oocyte and CKAMP39, CKAMP44 & CKAMP52 were injected at 1, 3 & 5 ng cRNA/oocyte, respectively. At these conditions, CKAMP39, CKAMP44 & CKAMP52 exhibited comparable protein expression levels ([Figure 3A](#fig3){ref-type="fig"}) without a significant influence on total current amplitude compared to oocytes expressing the AMPAR alone ([Supplementary file 1A](#supp1){ref-type="supplementary-material"}), thereby allowing better comparison between the CKAMPs in modulating AMPAR properties. Higher amounts of CKAMP cRNA injections caused a reduction in total current amplitude manifested by a reduction in total protein expression as revealed by Western-blot analysis with anti-GluA1 and anti-GluA2/3 antibodies, respectively (not shown).

Statistics {#s4-8}
----------

Data are presented as mean ± standard error of the mean (SEM) and as median ± interquartile range (IQR). Statistical differences between groups were examined by ANOVA, followed by Bonferroni test when the values showed a normal distribution, or by Kruskall-Wallis One Way ANOVA, followed by Dunn's method for multiple comparisons for non-Gaussian distributed values. Normality of data distribution was tested by Kolmogorov-Smirnov test and equal variance by Bartlett's test. Statistical analysis was performed using ORIGIN 8 (Origin Lab Corp.) or the GraphPad Prism version 5.00, GraphPad Software, San Diego, CA, USA, www.graphpad.com. P values \< 0.05 were considered statistically significant (\* = p \< 0.05, \*\* = p \< 0.01, \*\*\* = p \< 0.001, \*\*\*\* = p \< 0.0001).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"CKAMPs: a novel family of putative AMPA receptor auxiliary subunits\" for peer review at *eLife*. Your submission has been favorably evaluated by Gary Westbrook (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

All of the reviewers thought that the study is potentially interesting for the broad readership of *eLife*, and that your work provides a comprehensive analysis of the CKAMP family of AMPA receptor auxiliary factors. However, some major concerns should be carefully addressed in the revised version of the manuscript. In particular the location of bands related to the molecular weights of the various CKAMPs, for example CKAMP52 was unclear after comparing Figures 2B and 3A and needs further clarification. The reviewers also asked for surface biotinylation studies to determine if CKAMPs decrease surface expression of AMPA receptors in HEK293 cells as predicted by the authors. You will see that Reviewer 3 had many concerns regarding Figures 3-5, which may require clarifications in text or perhaps additional experiments. With respect to the CTZ experiments in Figure 4, the authors should clarify the text and explanations related to this entire Figure and in particular how the CTZ dose-response curves were performed. The reviewers understand that this study will be of considerable interest and it is therefore important to ensure that this first description is of the highest quality.

The main criticisms are listed below.

*Reviewer 1:*

It would be good if the authors could sum up future interesting questions which could be addressed such as the possible impact of the various AMPAR interacting proteins on the number of spines, synapse density and possible influence on the morphology of target cells.

*Reviewer 2:*

Because all of the conclusions drawn from results in heterologous cells rely on relatively equal expression of proteins it is crucial for the authors to address these discrepancies. The following issues should be addressed:

1\) Proposal that CKAMP members constitute a distinct protein family from that of Shisa members.

Figure 1: I assume that the sequences listed are from mouse but it is not stated in the legend. Reference to signal sequences and transmembrane domains should indicate that they are predictions or else experimental validation should be provided.

In the Results section, the authors state that, \"While CKAMP39 had only one splice variant, both CKAMP52 and CKAMP59 had two splice-isoforms (Figure 2---figure supplement 1). In the subsequent experiments, we utilized the most abundant versions of CKAMPs, i.e. CKAMP52 and CKAMP59 lacking exon 4.\" This observation is very interesting, especially if the primary amino acid sequence is altered upon addition of exon 4? In Figure 1, where is the additional sequence located upon inclusion of exon 4? Does this disrupt any of the protein-protein interacting domains such as the AMPA-R interacting domain or the PDZ motif? Do Shisa members exhibit similar splice variants with or without the inclusion of a variable exon?

2\) Distribution of CKAMP members in brain and AMPA-R interacting properties.

Figure 2B: How much input is in panel at left, 10% or 100%? This information should be in the figure legend. Where exactly is the flag-tag inserted? This information should be in Figure 1.

In the Discussion, the authors state that, \"The reduction of AMPAR mediated current amplitudes by all three CKAMPs in HEK293 cells was unexpected, since CKAMP44 has the opposite effect on AMPARs of granule cells, possibly by promoting trafficking of AMPARs to the cell surface.\" Because of the opposing results in HEK293 cells and granule cells, surface biotinylation should be carried out to determine if CKAMPs decrease surface expression of AMPA receptors in HEK293 cells as predicted.

Also in the Discussion, the authors state that, \"Indeed, the higher molecular weight -- especially of CKAMP52 -- in oocytes than in HEK293 cells (Figure 2B and 3A) is suggestive of such a difference.\" This statement is confusing because the lower band of CKAMP52 is similar to the single band of CKAMP44 in oocytes (Figure 3A) but both CKAMP52 bands are higher than CKAMP44 in HEK293 cells (Figure 2B). The authors state that the two bands reflect glycosylated versions of CKAMP59 and CKAMP52 in HEK293 cells (Figure 2B); therefore, it is unclear how the even greater molecular weight of CKAMP52 (almost at 100 kDa marker in Figure 3A) is achieved.

*Reviewer 3:*

1\) Figure 2 panel A, Adult brain. What happens to the CKAMP39 signal in the olfactory bulb between horizontal and sagittal sections? It\'s there in the horizontal but disappears in the sagittal. Also in Figure 2, why was GluA2 co-IP not done?

2\) In Figure 3, a blot including +CKAMP59 should be shown even if it has poor expression. Also, the glutamate concentration used should be stated in the legend or figure. In Figures 3 and 5 the deactivation time constants for GluA2 and GluA1 are unusually slow. The GluA1 looks to be about 2.5 ms (Figure 3B). Previous reports indicate that GluA1 deactivation is between 1 and 0.5 ms (Tomita et al., 2005 Figure 4D; Priel et al., 2005 Figure 2C; Bowie 2002 Figure 4, Partin et al., 1996 Figure 4) and GluA2 around 1 ms (C

arbone and Plested, Table 1. Why are deactivation time constants reported here 2 to 5 fold slower?

3\) Figure 3 uses mean +/- SEM but in Figure 5 the authors use median plus interquartile range. Why? Mean +/- SEM is standard. Also in Figure 5, panel D is not a recovery from desensitization experiment. Rather than long pulses to fully desensitize the channels, the authors use 1 ms pulse to evoke \'deactivation\' responses. This makes the experiment more of a paired pulse depression analogue than measuring recovery from desensitization (because the whole population doesn\'t actually desensitize). The authors should clearly state how long the pulses are (and not simply in the Methods) and unify their data presentation between Figure 3 and 5 (i.e. use either linear or log scale, IEI or time for panel D x axis).

4\) Although the authors use the open tip current method for measuring exchange, that only tells you about the exchange at the open tip, not solution exchange around the whole cell. See Barberis et al., 2008 Supplementary Material page 1 and Supplemental Figure 1). Given this, the authors should either repeat the experiments in patches, simply drop the HEK cell data and use only the oocytes, or insert a disclaimer to the effect of \'we know these aren\'t actually 1 ms pulses but they are only used to compare differences between CKAMPs\'.

5\) Figure 4A. There is no time scale for the traces. Also, if the authors want to measure steady-state (SS) current, then the traces should be shown reaching SS. As I understand the experiment, they compare the SS current observed with simultaneous glu and CTZ application (Figure 4A, a traces) versus pre-exposure to CTZ before glutamate (Figure 4A, b traces) as a control. Several things will happen if one applies glu and CTZ simultaneously apparently without CTZ pre-equilibration (a traces). The glu-bound channels will activate and quickly begin to enter the desensitized state. While CTZ binds to available dimer interfaces. Considering that CTZ binds the dimer interface, as the channels move from apo to open to desensitized states (and the dimer interface rearranges), the CTZ affinities of the various conformations of dimers will be dynamically changing during the agonist application. Amidst this complicated swirl of conformational changes, the desensitization rates of these various receptor conformations are also different (Figure 3C), which would be expected to alter the final SS current. Moreover, the CTZ potency is apparently also different (Figure 4B) so when the authors apply 100 uM CTZ to GluA1 it apparently occupies only about 45% of the receptors whereas at GluA1+39 it would occupy 10% of the receptors. These experiments are done in oocytes which have slow solution exchange so this experiment is not so much applying Glu + CTZ as it is slowly ramping up the concentration of glu + CTZ from zero to something apparently subsaturating. This makes it difficult to draw any mechanistic inference. Confusion is increased by the use of GluA3 in this part of the paper. Overall, it is not clear how much Figure 4A adds to the manuscript as currently presented.

6\) Figure 4B. Where is +CKAMP 44 or data for GluA2? Also, it is surprising that the EC50 for CTZ at GluA1 flip is 120 uM. Prior studies reported a value of 7 uM (Partin et al., 1994 Figure 2). Please address Figure 4 panels B and C (also in the text). In addition, the authors should use \"potency\" not \"affinity\". Affinity is only for kd. See Colquhoun (1998).

7\) Figure 4D. Because CKAMP44 and 52 appear to \'compete\' in this CTZ experiment, it does not provide evidence they \'form a protein family\' (subsection "Novel CKAMP members modify AMPAR-mediated currents in heterologous", third paragraph). TARPs or cornichon might do the same thing in such an assay. I suggest the authors remove this experiment. Should they wish to address this point, they could use TARPs or cornichon instead of Neto as a control and use GluA1 or 2 instead of 3.

In summary, Figure 4 could simply be CTZ dose-response curves (with explanation of how the curves were obtained, what conc. of glu for example) on GluA1, +39, +44 and +52 and GluA2 39, +44 and +52 as well as glutamate dose response curves with the same constructs.

10.7554/eLife.09693.015

Author response

We thank the reviewers for their constructive input and specific suggestions, which were instrumental in designing new experiments that helped improve the manuscript. We performed a number of additional experiments to address all concerns that were raised by the reviewers. One of the major criticisms raised

by Reviewer 2 was the lack of sufficient explanation for the reduction of AMPAR-mediated current amplitude by CKAMP family members. As suggested by the reviewer, we performed a biotinylation assay and found that CKAMP family members indeed reduce the number of surface AMPARs. Interestingly,

changes in total AMPAR expression and in the ratio of surface/total protein suggest that this reduction was in part due to an overall reduction in AMPAR protein, and in part due to a reduction in forward trafficking and/or stability of AMPARs on the cell surface. Reviewer 3 was in particular concerned with the interpretation of several experiments shown in Figure 4. To address his/her criticism, we performed a series of new experiments to estimate the influence of CKAMP family members on glutamate and cyclothiazide potency. In fact, nearly all panels of Figure 4 were replaced by panels showing new data providing evidence that all CKAMP family members increase glutamate potency and CKAMP39 and CKAMP52 decrease cyclothiazide potency.

We here provide a list of the figure panels presenting results that were not in the initial version:

Figure 2C: Co-IP of GluA2 with CKAMP family members

Figure 3A: New Western blot of CKAMP family members using the same blotting conditions and size marker that were also used for analyzing CKAMP family members expressed in HEK293 cells (i.e. Fig.2B and C).

Figure 4A: Investigation of glutamate potency (GluA1 and GluA2)

Figure 4B: Investigation of cyclothiazide potency (GluA1 and GluA2)

Figure 5---figure supplement 1: Biotinyltion assay for the quantification of surface and total GluA1 and GluA2 in HEK293 cells co-expressing CKAMP family members.

Reviewer 1:

*It would be good if the authors could sum up future interesting questions which could be addressed such as the possible impact of the various AMPAR interacting proteins on the number of spines, synapse density and possible influence on the morphology of target cells.*

We added future perspectives on the function of CKAMP family members in the Discussion.

Reviewer 2:

*1) Proposal that CKAMP members constitute a distinct protein family from that of Shisa members. Figure 1: I assume that the sequences listed are from mouse but it is not stated in the legend. Reference to signal sequences and transmembrane domains should indicate that they are predictions or else experimental validation should be provided.*

We added in the figure legends the information that the sequences refer to mouse proteins and that signal peptide and transmembrane domains are predicted.

*In the Results section, the authors state that, \"While CKAMP39 had only one splice variant, both CKAMP52 and CKAMP59 had two splice-isoforms (Figure 2---figure supplement 1). In the subsequent experiments, we utilized the most abundant versions of CKAMPs, i.e. CKAMP52 and CKAMP59 lacking exon 4.\" This observation is very interesting, especially if the primary amino acid sequence is altered upon addition of exon 4? In Figure 1, where is the additional sequence located upon inclusion of exon 4? Does this disrupt any of the protein-protein interacting domains such as the AMPA-R interacting domain or the PDZ motif? Do Shisa members exhibit similar splice variants with or without the inclusion of a variable exon?*

We agree that it is interesting that there are two splice variants of CKAMP52 and CKAMP59. In fact, there are also two splice variants of CKAMP44. At the moment we did not study the possible function of the alternatively spliced exons that encode for 32 and 17 amino-acids, respectively. However, the position of these amino-acids downstream of the AMPAR-interaction domain and upstream of the PDZ domain binding motif suggest that the spliced version lacking the alternatively spliced exon is unlikely to exhibit altered interaction with AMPARs or PDZ domain-containing proteins. No alternatively spliced mRNA of Shisa genes were reported. We included all required information in the text and figure legend of the manuscript.

*2) Distribution of CKAMP members in brain and AMPA-R interacting properties.*

*Figure 2B: How much input is in panel at left, 10% or 100%? This information should be in the figure legend. Where exactly is the flag-tag inserted? This information should be in Figure 1.*

We added the information in the figure legend of Figure 2B and in Figure 1.

*In the Discussion, the authors state that, \"The reduction of AMPAR mediated current amplitudes by all three CKAMPs in HEK293 cells was unexpected, since CKAMP44 has the opposite effect on AMPARs of granule cells, possibly by promoting trafficking of AMPARs to the cell surface.\" Because of the opposing results in HEK293 cells and granule cells, surface biotinylation should be carried out to determine if CKAMPs decrease surface expression of AMPA receptors in HEK293 cells as predicted.*

We thank the reviewer for suggesting we perform a biotinylation assay, since this experiment was indeed important to explain the reduction of AMPAR-mediated current amplitudes in HEK293 cells co-expressing CKAMP family members. Thus, the biotinylation assay revealed that CKAMP family members decrease the surface expression of AMPARs in HEK293 cells. Interestingly, this reduction could be explained in part by a reduction in total GluA1 and GluA2 expression and in part by a reduction of the forward trafficking or surface stability of AMPAPs, i.e. there was a reduction of total AMPAR expression and in addition a reduction in the ratio of surface/total AMPARs in cells expressing CKAMP family members. Finally, CKAMP family members seem to reduce the forward trafficking or surface stability in a subunit specific manner since the ratio of surface/total protein was reduced only for GluA2, but not for GluA1. In fact, CKAMP52 even increased the ratio of surface/total GluA1, thus appears to promote forward trafficking or surface stability of GluA1. We added a paragraph in which we describe the data and interpretation of these experiments.

*Also in the Discussion, the authors state that, \"Indeed, the higher molecular weight -- especially of CKAMP52 -- in oocytes than in HEK293 cells (Figure 2B and 3A) is suggestive of such a difference.\" This statement is confusing because the lower band of CKAMP52 is similar to the single band of CKAMP44 in oocytes (Figure 3A) but both CKAMP52 bands are higher than CKAMP44 in HEK293 cells (Figure 2B). The authors state that the two bands reflect glycosylated versions of CKAMP59 and CKAMP52 in HEK293 cells (Figure 2B); therefore, it is unclear how the even greater molecular weight of CKAMP52 (almost at 100 kDa marker in Figure 3A) is achieved.*

To rule out that differences in the blotting conditions explain the higher molecular weight in oocytes than in HEK293 cells, we performed repeatedly Western blots of CKAMPs in oocytes exactly reproducing conditions (buffers, incubation time etc.) that were employed to detect CKAMPs in HEK293 cells. However, the molecular weight of CKAMPs expressed oocytes is still higher than that of CKAMPs expressed in HEK293 cells, and in both expression systems the molecular weight is bigger than the calculated weight of CKAMPs. Since the same CKAMP constructs were used in oocytes and HEK293 cells, the most parsimonious explanation for this finding is a difference in the post-translational modification in mammalian and amphibian cells. However, the reviewer is correct that the statement about potential differences in posttranslational modifications might be confusing. Since we cannot prove that posttranslational modifications are the cause for the small difference in the observed function of CKAMPs in oocytes and HEK293 cells, we deleted this sentence from the Discussion.

Reviewer 3:

*1) Figure 2 panel A, Adult brain. What happens to the CKAMP39 signal in the olfactory bulb between horizontal and sagittal sections? It\'s there in the horizontal but disappears in the sagittal.*

The discrepancy of the CKAMP39 signals on the horizontal and sagittal sections is due to the fact that the olfactory bulb was severed from the sagittally sliced brain. We now show a section in which the olfactory bulb is present.

*Also in Figure 2, why was GluA2 co-IP not done?*

We performed additional experiments with Co-IP of GluA2 (shown in Figure 2B).

*2) In Figure 3, a blot including +CKAMP59 should be shown even if it has poor expression.*

We have added the blot that shows the absence of CKAMP59 expression in oocytes.

*Also, the glutamate concentration used should be stated in the legend or figure.*

We added the missing information.

*In Figures 3 and 5 the deactivation time constants for GluA2 and GluA1 are unusually slow. The GluA1 looks to be about 2.5 ms (Figure 3B). Previous reports indicate that GluA1 deactivation is between 1 and 0.5 ms (Tomita et al., 2005 Figure 4D; Priel et al., 2005 Figure 2C; Bowie 2002 Figure 4, Partin et al., 1996 Figure 4) and GluA2 around 1 ms (Carbone and Plested, Table 1). Why are deactivation time constants reported here 2 to 5 fold slower?*

The main reason for slow deactivation time constants is that we used macropatches (oocyte experiments) and whole-cells (HEK293 experiments) for quantification of the influence of CKAMPs on AMPAR kinetics. As noted also by Reviewer 3 (comment 4), solution exchange is significantly slower when applying glutamate onto whole-cells or macropatches compared to the fast solution exchange time when using small outside-out patches. In addition, room temperature was relatively low (we use shared facilities that require a constant temperature of 17°C) when oocyte experiments were performed, which would also slow deactivation kinetics.

We could not use outside-out patches since AMPAR-mediated current amplitudes were reduced too strongly in patches of cells that co-expressed CKAMPs. A reliable quantification of AMPAR kinetics was not possible from patches with very small current amplitudes. Thus, these experiments are indeed suboptimal for quantifying the \"real\" influence of CKAMP on AMPAR deactivation kinetics. However, we believe that we still can infer from these experiments that CKAMP39 and CKAMP52 slow AMPAR deactivation.

*3) Figure 3 uses mean +/- SEM but in Figure 5 the authors use median plus interquartile range. Why? Mean +/- SEM is standard.*

Data from Figure 5 were not normally distributed. Thus, we tested for statistical differences between groups by Kruskall-Wallis One Way ANOVA. Accordingly, we decided to show median + IQR for these not normally distributed data. However, if the reviewer believes that we should be consistent in the way how to present data, we could change to mean +/- SD also in this figure.

*Also in Figure 5, panel D is not a recovery from desensitization experiment. Rather than long pulses to fully desensitize the channels, the authors use 1 ms pulse to evoke \'deactivation\' responses. This makes the experiment more of a paired pulse depression analogue than measuring recovery from desensitization (because the whole population doesn\'t actually desensitize). The authors should clearly state how long the pulses are (and not simply in the Methods) and unify their data presentation between Figure 3 and 5 (i.e. use either linear or log scale, IEI or time for panel D x axis).*

We did not perform a classical recovery from desensitization experiment but wanted to get an idea about the recovery from desensitization of AMPA receptors that are exposed to glutamate for a short time (similar to the short presence of glutamate in the synaptic cleft). From our previous studies we knew that CKAMP44 reduces synaptic short-term plasticity in synapses of dentate gyrus granule cells despite the short presence of glutamate in the synaptic cleft. CKAMP39 in fact slows recovery from desensitization similar to CKAMP44 (Khodosevich et al., Neuron 2014) suggesting that it also could influence short-term plasticity in synapses with high release probability. We have added more information to the Results about the experiment and unified data presentation of Figures 3 and 5.

*4) Although the authors use the open tip current method for measuring exchange, that only tells you about the exchange at the open tip, not solution exchange around the whole cell. See Barberis et al., 2008 Supplementary Material page 1 and Supplemental Figure 1). Given this, the authors should either repeat the experiments in patches, simply drop the HEK cell data and use only the oocytes, or insert a disclaimer to the effect of \'we know these aren\'t actually 1 ms pulses but they are only used to compare differences between CKAMPs\'.*

Indeed, an analysis of AMPA receptors with patches would have been better. Unfortunately, we could not perform the analysis on patches, because of the dramatic reduction in AMPA receptor number on the cell surface in cells that co-expressed CKAMPs. In many patches, currents were simply too small for an analysis of kinetics. However, we would like to show the data since we believe that despite the comparably slow application the results of the HEK293 cell experiments add some information about differences in the function of CKAMPs. Thus, we would prefer to add -- as suggested -- the information that glutamate pulses are slower when applied onto whole-cells instead of patches.

*5) Figure 4A. There is no time scale for the traces. Also, if the authors want to measure steady-state (SS) current, then the traces should be shown reaching SS. As I understand the experiment, they compare the SS current observed with simultaneous glu and CTZ application (Figure 4A, a traces) versus pre-exposure to CTZ before glutamate (Figure 4A, b traces) as a control. Several things will happen if one applies glu and CTZ simultaneously apparently without CTZ pre-equilibration (a traces). The glu-bound channels will activate and quickly begin to enter the desensitized state. While CTZ binds to available dimer interfaces. Considering that CTZ binds the dimer interface, as the channels move from apo to open to desensitized states (and the dimer interface rearranges), the CTZ affinities of the various conformations of dimers will be dynamically changing during the agonist application. Amidst this complicated swirl of conformational changes, the desensitization rates of these various receptor conformations are also different (Figure 3C), which would be expected to alter the final SS current. Moreover, the CTZ potency is apparently also different (Figure 4B) so when the authors apply 100 uM CTZ to GluA1 it apparently occupies only about 45% of the receptors whereas at GluA1+39 it would occupy 10% of the receptors. These experiments are done in oocytes which have slow solution exchange so this experiment is not so much applying Glu + CTZ as it is slowly ramping up the concentration of glu + CTZ from zero to something apparently subsaturating. This makes it difficult to draw any mechanistic inference. Confusion is increased by the use of GluA3 in this part of the paper. Overall, it is not clear how much Figure 4A adds to the manuscript as currently presented.*

We agree with the reviewer. It is rather difficult to draw conclusions from the experiment with co-application of glutamate and CTZ. Thus, we performed additional experiments in which we quantified the CTZ EC50 for GluA1 and GluA2 by applying glutamate and the respective CTZ concentration onto oocytes after 10 sec application of CTZ alone.

*6) Figure 4B. Where is +CKAMP 44 or data for GluA2? Also, it is surprising that the EC50 for CTZ at GluA1 flip is 120 uM. Prior studies reported a value of 7 uM (Partin et al., 1994 Figure 2). Please address Figure 4 panels B and C (also in the text). In addition, the authors should use \"potency\" not \"affinity\". Affinity is only for kd. See Colquhoun (1998).*

The lower CTZ EC50 is explained by the co-application protocol. As noted by the reviewer in the previous comment, current amplitude was quantified 10 sec after glutamate + CTZ co-application; indeed no real SS current was reached. We repeated these experiments by including 10 sec pre-incubation of the oocyte with CTZ alone, before its co-application with glutamate to reach an equilibrium SS current (as done by Partin et al., 1994). Under these conditions a significant lower EC50 was found. The difference of the CTZ EC50 in our study (15 µM) and the study of Partin et al. (7 µM) might be due to technical differences (e.g. we used 1 mM glutamate and Partin et al. used 300 µM kainate to activate AMPARs). We corrected for potency instead of affinity.

*7) Figure 4D. Because CKAMP44 and 52 appear to \'compete\' in this CTZ experiment, it does not provide evidence they \'form a protein family\' (subsection "Novel CKAMP members modify AMPAR-mediated currents in heterologous", third paragraph). TARPs or cornichon might do the same thing in such an assay. I suggest the authors remove this experiment. Should they wish to address this point, they could use TARPs or cornichon instead of Neto as a control and use GluA1 or 2 instead of 3.*

We agree with the reviewer and deleted the experiment.

*In summary, Figure 4 could simply be CTZ dose-response curves (with explanation of how the curves were obtained, what conc. of glu for example) on GluA1, +39, +44 and +52 and GluA2 39, +44 and +52 as well as glutamate dose response curves with the same constructs.*

We followed the suggestion of the reviewer.

[^1]: BRIC -- Biotech Research and Innovation Center, Copenhagen University, Copenhagen, Denmark.

[^2]: These authors contributed equally to this work.

[^3]: These authors also contributed equally to this work.
